Home » Stocks » MTCR

Metacrine, Inc. (MTCR)

Stock Price: $3.37 USD 0.00 (0.00%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 88.33M
Revenue (ttm) 2.18M
Net Income (ttm) n/a
Shares Out 26.21M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $3.37
Previous Close $3.37
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.37
Day's Range 3.30 - 3.47
Day's Volume 41,802
52-Week Range 3.30 - 16.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...

4 days ago - GlobeNewsWire

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...

1 month ago - GlobeNewsWire

Interim Data from the Phase 2a Trial of MET642 in NASH Patients On-Track to be Reported in the Fourth Quarter of 2021

1 month ago - GlobeNewsWire

Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers Sustained pharmacodynamic effects with once-daily ...

2 months ago - GlobeNewsWire

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with ...

2 months ago - GlobeNewsWire

On-track for Interim Analysis Readout in the Fourth Quarter of 2021 On-track for Interim Analysis Readout in the Fourth Quarter of 2021

2 months ago - GlobeNewsWire

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with ...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...

2 months ago - GlobeNewsWire

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed t...

Other stocks mentioned: ABIO, ATHA
2 months ago - GuruFocus

Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evidence that t...

2 months ago - GlobeNewsWire

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...

3 months ago - GlobeNewsWire

Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs Trial Designed to Evaluate Potential of FXR-Based Combi...

4 months ago - GlobeNewsWire

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase

4 months ago - GlobeNewsWire

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...

5 months ago - GlobeNewsWire

Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH

6 months ago - GlobeNewsWire

New Data Support Robust, Sustained FXR Activation by MET409 in Patients with NASH and Demonstrate Predictability of Liver Fat Reductions as Early as Week 4 of Treatment New Data Support Robust, Sustaine...

7 months ago - GlobeNewsWire

Did you miss the Metacrine IPO? No worries.

7 months ago - InvestorPlace

Shares of Metacrine Inc. got a bullish start to their public life, as they opened 10.7% their initial public offering price.

7 months ago - Market Watch

About MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of ... [Read more...]

Industry
Biotechnology
IPO Date
Sep 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
MTCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Metacrine stock is "Strong Buy." The 12-month stock price forecast is 19.83, which is an increase of 488.43% from the latest price.

Price Target
$19.83
(488.43% upside)
Analyst Consensus: Strong Buy